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Abstract
Data of previous trials with a similar setting are often available in the analysis of clinical trials. Several Bayesian methods
have been proposed for including historical data as prior information in the analysis of the current trial, such as the
(modified) power prior, the (robust) meta-analytic-predictive prior, the commensurate prior and methods proposed by
Pocock and Murray et al. We compared these methods and illustrated their use in a practical setting, including an
assessment of the comparability of the current and the historical data. The motivating data set consists of randomised
controlled trials for acute myeloid leukaemia. A simulation study was used to compare the methods in terms of bias,
precision, power and type I error rate. Methods that estimate parameters for the between-trial heterogeneity generally
offer the best trade-off of power, precision and type I error, with the meta-analytic-predictive prior being the most
promising method. The results show that it can be feasible to include historical data in the analysis of clinical trials, if an
appropriate method is used to estimate the heterogeneity between trials, and the historical data satisfy criteria for
comparability.
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1 Introduction
Clinical trials are seldom performed in isolation. In many cases, data of previous trials with a similar setting are
available. Such historical data may provide information that is relevant to the research questions of the current
trial.1 Including these historical data in the analysis of the current trial could improve the precision of the
estimates, thereby increasing statistical power for hypothesis testing and reducing required sample sizes. The
investigational treatment usually diﬀers between trials, but the treatment in the control arm often remains
stable over successive trials, so that only the control arms of previous trials are eligible for inclusion in the
analysis of the current trial.
Diﬀerences in patient populations or other trial-speciﬁc circumstances can lead to heterogeneity among the
historical trials and between the current trial and the historical trials. When including historical data in the analysis
of a clinical trial, one should thus account for the possible heterogeneity between the trials. In case of large
discrepancies between the historical trials and the current trial, the historical data should not inﬂuence the
results of the analysis of the current trial.
In a seminal paper, Pocock1 proposed a statistical method that accounts for a diﬀerence in model parameters
between the historical and the current data and treats this diﬀerence as a random variable. In recent years, there
has been a renewed interest in methods for including historical data in the analysis of clinical trials. Ibrahim and
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Chen,2 Duan et al.3 and Neuenschwander et al.4 proposed the power prior and the modiﬁed power prior,
i.e. Bayesian methods that use an informative prior based on the likelihood function of the historical data for
the analysis of the current trial. These methods downweight the information in the historical data, to account for
potential diﬀerences between historical and current data. Neuenschwander et al.5 described the use of meta-
analytic methods to account for heterogeneity in model parameters between historical and current data and to
determine the posterior distribution of the parameters for the current trial. Schmidli et al.6 extended these meta-
analytic methods by adding a robust component, to account for the possibility of a conﬂict between historical and
current data. Hobbs et al.7 developed the commensurate prior for various types of generalised linear mixed
models, including models for time-to-event outcomes. In this method, the priors for the model parameters for
the current data are centred at the corresponding parameters for the historical data, and a distribution is assumed
for the diﬀerence in model parameters between the current and historical data. Murray et al.8 extended the
commensurate prior to piecewise exponential survival distributions, using a ﬂexible semi-parametric approach
for combining historical and current data. All these methods are based on a Bayesian statistical framework, which
seems natural when using historical data as prior information.
The historical trials used for these statistical methods should be chosen carefully, to ensure suﬃcient
comparability with the current trial. The most commonly used criteria for assessing the comparability of the
historical and the current trials are those proposed by Pocock.1 It is necessary to impose such comparability
criteria, as the statistical methods for including historical data are based only on the results of the current and
historical trials and do not take into account the context in which these trials were performed.
The inclusion of historical data in the analysis of clinical trials is not yet common in practice. One reason is that
it is not yet clear which statistical method should be used, and practical experience with these methods is limited. In
addition, it is not yet fully known in what kinds of settings the historical and current data are suﬃciently
comparable, and how strictly comparability criteria such as Pocock’s criteria should be upheld. Finally,
although previous studies have assessed the type I error and power of some methods in relatively simple
models,9,10 a comprehensive overview of the frequentist characteristics of the available methods, and how these
outcomes depend on the between-trial heterogeneity, is not yet available. Therefore, regulatory authorities and
other decision makers may not easily accept the inclusion of historical data into the planning and analysis of
clinical trials.
In this paper, we give an overview of methods for including historical data in the analysis of clinical trials. We
illustrate what kind of results these methods yield in a practical setting, and we assess the comparability of the
current and the historical data. A simulation study is performed to compare the methods in terms of bias,
precision, power and type I error rate.
This paper focuses on the analysis of survival data. The motivating data set consists of a number of randomised
controlled trials for acute myeloid leukaemia (AML) that were conducted by the Dutch-Belgian Hemato-
Oncology Cooperative Group (HOVON). The next section describes the HOVON data and evaluates to what
extent these data satisfy comparability criteria. Section 3 gives an overview of methods for including historical data
in the analysis of clinical trials. Section 4 describes the analysis and the results of the HOVON data. Section 5
presents the design and the results of the simulation study, and Section 6 concludes.
2 Motivating data set: HOVON data
AML is a cancer of the myeloid line of blood cells, with ﬁve-year survival rates in diﬀerent patient populations
ranging from 15% to 70%, depending on age and other factors. Despite a large amount of research, the available
treatment options and the survival rate of AML have changed relatively slowly over time. Treatment of AML
consists primarily of chemotherapy, which includes two phases: induction and consolidation therapy. Stem cell
transplantation is usually considered if (a) the estimated risk of relapse is substantial after induction therapy,
(b) induction chemotherapy fails, or (c) if the patient relapses.
HOVON has performed a number of randomised controlled trials on chemotherapy treatments for patients
with AML since the 1980s.11–15 Each trial had its own control arm, but the control arm treatments were similar.
Because AML is a relatively rare disease, it often takes several years of inclusion and large-scale international
collaborations to recruit suﬃcient patients for a clinical trial. In this context, it is natural to consider previous
HOVON AML trials for the analysis of a new trial. Ideally, this approach would enable researchers to design new
AML trials with smaller control arms, thereby increasing the speed and the eﬃciency of the research. This prospect
motivated the use of the HOVON data in this article. However, before including historical data in the analysis, the
comparability of the historical trials and the current trial should be assessed.
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2.1 Description of the data
We consider the analysis of the HOVON 42A trial, which investigated the eﬀect of priming using a
granulocyte colony-stimulating factor (G-CSF) in the remission induction chemotherapy course for treatment
of AML. HOVON 42A is an extension of the HOVON 42 trial, which also considered the eﬀect of
G-CSF priming. However, HOVON 42 also included a randomisation for the dose of cytarabine
(a chemotherapy agent) to either a conventional dose or an escalated dose, whereas all patients in HOVON
42A received the conventional cytarabine dose. An analysis of the eﬀect of G-CSF using the combined data of
HOVON 42 and HOVON 42A has been published,14 and no signiﬁcant eﬀect of G-CSF priming was found in the
overall analysis.
In this paper, we treat HOVON 42A as the current trial and HOVON 42 as a separate study. We consider
the inclusion of historical data of the trials HOVON 4,11 HOVON 4A, HOVON 2912 and HOVON 4213 to
improve the analysis of HOVON 42A. Each trial used a 1:1 randomisation for the treatment in the induction
phase, with the investigational treatment diﬀering between trials. The control treatment in these trials consisted
of one cycle of induction with an anthracycline (daunorubicin or idarubicin) in combination with cytarabine
(200mg=m2 for seven days) and a second cycle of amsacrine with intermediate-dose cytarabine (1000mg=m2
every 12 h for six days). There were three types of post-remission therapy: (a) a continued third cycle of
chemotherapy (so-called consolidation chemotherapy), (b) autologous stem cell transplantation (i.e. the
patient’s own marrow or peripheral blood serves as the stem cell graft) or (c) allogeneic stem cell
transplantation (i.e. a healthy donor’s marrow or peripheral blood serves as the stem cell graft). The choice
of these post-remission therapies depended not only on the availability of a donor but also on the age of the
patient and the prognostic risk features of the leukaemia. A second randomisation for the post-remission
therapy treatment was used in HOVON 29 and HOVON 42, but only for a select subgroup of patients. In
these two trials, the patients eligible for an autologous stem cell transplant were randomised between an
autologous transplant and consolidation chemotherapy. Event-free survival and overall survival were
important endpoints for each trial. The trials were approved by the ethics committees of the participating
institutions and were conducted in accordance with the Declaration of Helsinki. All participants gave their
informed consent.
We note that some of the historical HOVON trials used the same or a similar investigational treatment as the
current trial. However, to obtain the usual setting where only the control arm treatments remain stable over
successive trials, we excluded the patients treated with G-CSF in the historical trials from the analysis. We also
excluded patients who received an escalated cytarabine dose in HOVON 42, as well as patients with AML subtype
M3 according to the French-American-British classiﬁcation. We only consider the outcome of overall survival.
Table 1 presents descriptive statistics of the selected patients.
Table 1. Descriptive statistics of selected patients in HOVON AML trials.
Trial HOVON 4 HOVON 4A HOVON 29 HOVON 42 HOVON 42A
Number of patients 359 252 693 437 511
Number of deaths 277 (77.2%) 181 (72.1%) 474 (68.4%) 293 (67.0%) 294 (57.5%)
Age 44 (34–53) 43 (33–51) 45 (35–54) 49 (39–55) 50 (39–56)
Gender (female) 49.9% 45.0% 49.4% 44.4% 48.5%
Randomisation year 1989 (1988–1992) 1992 (1992–1993) 1999 (1997–2000) 2003 (2002–2004) 2007 (2006–2008)
Complete response 77.7% 82.5% 86.0% 81.9% 83.2%
White blood cell count 14.7 (4.6–56.2) 14.9 (4.3–48.8) 13.6 (3.4–47.6) 11.6 (3.5–46.0) 11.2 (2.7–41.7)
Cytogenetic subgroup (karyotype)
t(8;21) 8.5% 11.3% 6.7% 5.3% 3.9%
inv(16) 6.1% 6.3% 7.3% 4.6% 4.7%
t(15;17) 0.3% 0.5% 0.3% 0.0% 0.0%
Cytogenetically normal 48.8% 49.1% 51.9% 47.5% 47.5%
Cytogenetically abnormal 25.6% 24.8% 24.9% 32.1% 29.0%
Monosomal karyotype 10.6% 8.1% 8.9% 10.6% 14.8%
Note: Continuous variables are described using medians and interquartile ranges, and categorical variables using percentages.
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2.2 Evaluation of comparability criteria
For the selected HOVON trials, an evaluation of Pocock’s criteria for the comparability of historical and current
controls is as follows:
. P1: The historical controls must have received a precisely deﬁned standard treatment which must be the same as the
treatment for the randomised controls.
In each trial, the initial treatment consisted of two cycles of chemotherapy for the induction treatment. The type
of chemotherapy and the dose were the same in each control arm, but the consolidation phase treatment could
diﬀer. Some trials used an additional randomisation for the consolidation phase treatment. For these trials, the
second randomisation concerned only the patients eligible for an autologous stem cell transplantation.
. P2: The historical controls must have been part of a recent clinical study which contained the same requirements for
patient eligibility.
The HOVON trials have been performed over a considerable period of time. The ﬁrst patient was registered in
July 1987 for HOVON 4, in October 1990 for HOVON 4A, in March 1995 for HOVON 29, in January 2001 for
HOVON 42 and in February 2006 for HOVON 42A. Although the available treatment options for AML have
changed relatively slowly, the improvements in bone-marrow transplantation techniques and supportive care
over a time span of 20 years can be substantial, such as new antibiotics, better antimicrobial prophylaxis and
treatment, better blood transfusion support and other changes in medical care. Some of the historical trials used
a slightly wider age range as inclusion criterion than HOVON 42A, which used an age range of 18–60 years.
. P3: The methods of treatment evaluation must be the same.
We use the endpoint of overall survival for all trials, and this outcome is measured in the same way in all trials.
. P4: The distributions of important patient characteristics in the historical controls should be comparable with those
in the new trial.
There were statistically signiﬁcant diﬀerences between trials in the distribution of age (Kruskal–Wallis test,
p< 0.001) and the cytogenetic subgroup (chi-square test, p¼ 0.002), which are important prognostic factors for
AML survival. There were no signiﬁcant diﬀerences in the distribution of gender (chi-square test, p¼ 0.38) and
the white blood cell count (Kruskal–Wallis test, p¼ 0.13).
. P5: The previous studies must have been performed in the same organisation with largely the same clinical
investigators.
All trials were initiated and sponsored by HOVON. There have been relatively few changes in the organisation
and structure of HOVON, though the number of associated treatment centres has increased over time.
. P6: There must be no other indications leading one to expect diﬀering results between the randomised and historical
controls.
Concomitant medications and overall quality of care may have improved over time. To our knowledge, there
are no other indications for substantial diﬀerences between the trials.
This evaluation suggests that it is doubtful whether criteria P2 and P4 are satisﬁed, whereas the other
Pocock criteria are satisﬁed to a large extent. We conclude that HOVON 4 and 4A are too old to be
considered relevant for the analysis of HOVON 42A, and these trials are thus excluded from the analysis. The
time gap among the three remaining trials (HOVON 29, 42 and 42A) is substantial with almost 11 years between
the start dates of HOVON 29 and HOVON 42A. However, we do not consider this time gap to be too long, as
modern antibiotics, antimicrobial prophylaxis and treatment and blood transfusion support were already available
at the start of HOVON 29. To account for the diﬀerences in age range between trials, only patients with age
between 18 and 60 years (i.e. the age range of HOVON 42A) were included in the analysis. Even after that
correction, the age distribution diﬀered signiﬁcantly between trials, which was addressed by including age as a
covariate in the analysis. Although there are some diﬀerences in the distribution of the cytogenetic subgroup
between trials, we decided not to adjust for this variable in the analysis, as these diﬀerences are relatively small and
partially explained by the diﬀerences in age distribution. Molecular biomarkers are also relevant predictors of
survival among AML patients, but these were not available for the older trials, so that no comparison was
possible.
As an alternative to using Pocock’s criteria, we could assume exchangeability of the historical trials and the
current trial,16 which is a necessary assumption for several hierarchical methods (see the next section).
Exchangeability implies that the parameters that generated the data of the diﬀerent trials are drawn from the
same (normal) distribution, and that there is no natural ordering of the trials. Of course, there is a natural ordering
of the HOVON trials, namely the time period during which each trial was performed. This means that a time
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trend in the outcome (overall survival) would violate the assumption of exchangeability. Figure 1 shows the
Kaplan–Meier estimates for overall survival in each control arm and in the investigational arm of HOVON
42A. The log-rank test revealed no signiﬁcant diﬀerences in survival between the control arms of the included
trials (p¼ 0.13); however, the diﬀerences were signiﬁcant after adjusting for age using a Cox regression (p¼ 0.035).
The diﬀerence in overall survival between the treatment arms of HOVON 42A was not signiﬁcant (log-rank test,
p¼ 0.29).
3 Methods for including historical data
We assume that a current trial is available with likelihood function LðjDÞ, and K historical trials with
likelihood functions LðjHkÞ, k ¼ 1, . . . ,K and pooled likelihood LðjHÞ, where D represents the current
data and H ¼ fH1, . . . ,HKg represents the historical data. The current trial is assumed to consist of one
investigational arm and one control arm, and for the historical trial(s), only the control arm data are used. The
parameters  can be decomposed as  ¼ fI, Cg, where I describes the intervention eﬀect (i.e. the diﬀerence
between the trial arms), and C describes the distribution of the control arm data. In some methods, diﬀerent
model parameters are assumed for the historical and the current data. Below, we describe the methods for
incorporating historical data using the likelihood functions of the trials, but ignoring the distributions of
individual observations.
3.1 Pocock’s method
Pocock’s method assumes that the historical data are a potentially biased representation of the distribution of the
data in the current trial.1 The bias is formally described as  ¼ CD  CH , where CD and CH describe the
distribution (e.g. the mean outcome) of the current controls and the historical controls, respectively. The
direction of the bias  is typically unknown, and in Pocock’s method, this bias is assumed to be normally
distributed with mean 0, so that   Nð0, 2 Þ. We use the term bias to describe the diﬀerence , as this term
was also used by Pocock. However, the size of  and thus the value of 2 actually indicate the amount of between-
trial heterogeneity. Pocock’s method only accounts for bias in a single parameter, though this method can be used
in models with multiple parameters for the distribution of the control arm data.
It is diﬃcult to estimate 2 using the observed data if only a single or a small number of historical trials are
available. Therefore, Pocock suggested that the researcher specify plausible values for 2 instead of estimating it.
The posterior distribution of the parameters using Pocock’s method is given by
pPocockðI, CD , j2 ,D,HÞ / LðI, CD jDÞNðj0, 2 ÞLðCD  jHÞðIÞðCDÞ ð1Þ
Figure 1. HOVON data: Kaplan–Meier curves of overall survival in the control arms of the HOVON trials, and the investigational
arm of HOVON 42A.
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where ðIÞ and ðCDÞ are uninformative priors for the model parameters. In case of multiple historical trials, we
assume that the bias varies randomly between trials, so that the posterior is then given by
pPocockðI, CD , 1, . . . , Kj2 ,D,HÞ / LðI, CD jDÞ
YK
k¼1
Nðkj0, 2 ÞLðCD  kjHkÞ
 !
ðIÞðCDÞ ð2Þ
3.2 Power prior and modified power prior
The idea of the power prior2,17 is to incorporate the historical data by using a downweighted version of the
likelihood of the historical data as prior. This downweighting is achieved by raising the likelihood to a power
, with 0    1. Unlike Pocock’s method, the power prior assumes a common set of model parameters C for the
historical controls and the current controls. The power prior is deﬁned as
PPðCj,HÞ / LðCjHÞðCÞ ð3Þ
and yields the posterior distribution
pPPðI, Cj,D,HÞ / LðI, CjDÞLðCjHÞðCÞðIÞ ð4Þ
where ðCÞ and ðIÞ are uninformative priors. For the case of multiple historical trials, Chen et al.18 suggested to
use a diﬀerent weight parameter for each historical trial. However, as it is unclear how such diﬀerential weights
should be chosen, we prefer to use the same weight for each trial.
Using the power prior, the weight parameter  must be chosen in advance. Setting ¼ 1 leads to a complete
pooling of the data of the historical and current data, whereas setting ¼ 0 eﬀectively discards the historical data.
The parameter  can be interpreted as a precision parameter, as for many classes of models the power prior can
asymptotically be approximated as PPðCj,HÞ  NðbC,1G1ðbCÞÞ, where bC is the mode of the power prior
and GðCÞ ¼  @2@C@ 0C logðPPðCj,HÞÞ.
17 It is in general not clear how  should be chosen, though Ibrahim
et al.17,19 have proposed to use the deviance information criterion or the logarithm of the pseudo marginal
likelihood.
An alternative approach is to estimate  using the available data. This can be done with the modiﬁed power
prior (MPP),3,4 which yields the posterior distribution
pMPPð, I, CjD,HÞ / LðI, CjDÞ 1
CðÞLðCjHÞ
ðCÞðIÞðÞ ð5Þ
where CðÞ ¼ RC LðCjHÞðCÞdC is a scaling constant that depends only on . The inclusion of this scaling
constant ensures that the results satisfy the likelihood principle.3,20
A diﬃculty of the MPP is that the integral in the scaling constant CðÞ must be calculated in every iteration
of a Markov chain Monte Carlo (MCMC) sampler, which can be very time-consuming. This is especially
problematic in case the number of parameters in  is large, so that numerical or analytical integration
becomes infeasible. To solve this problem, we developed a novel algorithm for calculating the scaling
constant, based on an algorithm for calculating the marginal likelihood (i.e.
R
C
LðCjHÞðÞdC with ¼ 1)
using power posteriors that was proposed by Friel and Petitt.21 A simple adaptation of their algorithm enables
the calculation of
R
C
LðCjHÞðÞdC for 0    1. The steps of this algorithm are described in the
supplementary material.
Furthermore, it is not yet clear how the MPP should be extended to the case of multiple historical data sets.
Several formulations, with diﬀerent deﬁnitions of the scaling constant, were proposed by Duan,22 but practical
experience with these formulations is lacking.
3.3 Meta-analytic-predictive approach
Neuenschwander et al.5 proposed a method for including historical data based on meta-analytic techniques. This
meta-analytic-predictive (MAP) approach assumes that the model parameters of all trials are exchangeable and
are drawn from the same normal distribution. With a single outcome parameter that diﬀers between trials, the
6 Statistical Methods in Medical Research 0(0)
study-speciﬁc parameters are given by
CHk ¼  þ k, k ¼ 1, . . . ,K and CD ¼  þ Kþ1 ð6Þ
where CHk and CD denote the outcome parameter for the k-th historical trial and the current control arm,
respectively,  is the population mean of these parameters and k is a normally distributed error term with
k  Nð0, 2Þ. The MAP approach diﬀers from conventional meta-analysis in that it aims to predict the outcome
parameter for the current trial (i.e. CD) instead of the overall mean outcome .
The implementation of this method requires the estimation of the between-study variance 2 , for which several
approaches were proposed by Neuenschwander et al.5 We estimate 2 in a fully Bayesian way, which yields the
following posterior:
pMAPðI,, 1, . . . , K, Kþ1, 2 jD,HÞ / NðKþ1j0, 2Þ
 LðI, þ Kþ1jDÞ
YK
k¼1
Nðkj0, 2ÞLð þ kjHkÞ
 !
ðIÞðÞð2Þ
ð7Þ
Because the posterior results may be sensitive to ð2Þ, a sensitivity analysis is recommended, especially if the
number of historical trials is low.
Schmidli et al.6 proposed a ‘robustiﬁcation’ of the MAP approach to account for the possibility that the
historical data and the current data are in conﬂict. In this robust MAP approach, the hierarchical model of the
MAP approach is ﬁrst estimated using only the historical data, yielding the posterior
MAPðI,, 1, . . . , K, 2jHÞ /
YK
k¼1
Nðkj0, 2ÞLð þ kjHkÞ
 !
ðIÞðÞð2Þ ð8Þ
Applying this posterior as prior distribution for an analysis of the current trial yields the same posterior for the
MAP approach as in equation (7), see the proof given by Schmidli et al.
In the robust MAP approach, a robust (i.e. less informative) component is added to the prior for the analysis of
the current data according to
robustMAP ¼ ð1 wrÞMAP þ wrrobust ð9Þ
where wr denotes the size of the robust component, robust is a vague prior for the model parameters and the model
parameters have been omitted for brevity. The vague prior of the robust component serves to account for data in
which the diﬀerence between historical and current data exceeds the heterogeneity among the historical trials. To
implement this method, it is typically necessary to approximate MAP with a parametric distribution, so that it can
be used in the prior for the analysis of the current data.
3.4 Commensurate prior and method of Murray et al.
The commensurate prior model was developed by Hobbs et al.7,23 In this model, the distribution of the
parameters for the current trial is centred on the corresponding parameters for the historical data, so that the
prior is given by
CPðI, CD jCH , 2 ,HÞ / NðCD jCH , 2 ÞLðCH jHÞðIÞðCDÞ
where 2 parameterizes the variance of CD given CH and thus speciﬁes the amount of between-trial heterogeneity.
The commensurate prior model accounts for between-trial heterogeneity in a single parameter.
Hobbs et al.7 described several ways to estimate the heterogeneity between historical and current data in the
commensurate prior, including a fully Bayesian approach, which yields the following posterior:
pCPðI, CD , CH j2 ,D,HÞ / NðCD jCH , 2 ÞLðI, CD jDÞLðCH jHÞðIÞðCH Þð2 Þ ð10Þ
where ð2 Þ is the prior for 2 .
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Murray et al.8 proposed a fully Bayesian approach for incorporating data of historical trials with time-to-event
outcomes. Their method can be seen as a speciﬁc implementation of the commensurate prior, with a ﬂexible
piecewise exponential speciﬁcation for the baseline hazard and a correlated prior process. The parameters for the
baseline hazard function and the covariate eﬀects in the current trial are centred on the corresponding parameters
for the historical data. Spike-and-slab prior distributions24 are used to model the variances of these parameters for
the current data, conditional on the parameters of the historical data. The method of Murray et al. assumes that
there is only a single historical data set.
3.5 Test-then-pool approach
Viele et al.10 describe a simple frequentist approach to determine how the historical data are included. This test-
then-pool (TTP) approach consists of performing a frequentist test to determine whether there is a signiﬁcant
diﬀerence in distribution between the historical and the current controls. If the p-value of this test is lower than a
prespeciﬁed cut-oﬀ value (e.g. 0.05), the analysis is done with only the current data, otherwise the historical data
are fully included in the analysis.
3.6 Relationships between methods
Several of these methods are related to each other. Pocock’s method, the MAP approach and the commensurate
prior are similar in that these methods assume or estimate a variance parameter for the between-trial
heterogeneity. Pocock’s method is equivalent to the commensurate prior for a single historical trial, except that
the between-study variance is not estimated but set in advance. Pocock’s method can also be seen as a special case
of the MAP approach with a single historical trial, with the variance of the bias 2 speciﬁed as 0:5
2
 , to account for
the diﬀerent parameterisations of the heterogeneity.
The power prior and the MPP constitute a diﬀerent family of methods, due to the weight parameter for the
historical data. However, even these methods are related to the other methods. Chen and Ibrahim25 showed that in
linear and generalised linear models, the results of the power prior correspond with the results of hierarchical
models (i.e. the MAP approach), provided that the weight parameter  equals a speciﬁc function of the parameters
of the hierarchical model, and that certain types of priors are used.
4 Statistical analysis of the HOVON trials
Based on the evaluation of Pocock’s criteria, we used data of HOVON 29 and 42 as historical trials to help
estimate the intervention eﬀect in HOVON 42A with the methods described in Section 3. To compare these
methods with standard approaches, we also performed a pooled Bayesian analysis that includes the data of all
trials without accounting for between-trial heterogeneity, and a Bayesian analysis of only the current trial; these
methods are referred to as ‘Pooled data’ and ‘Current data’, respectively.
All Bayesian methods were implemented using a proportional hazards survival model with overall survival
(until the end of follow-up) as outcome and treatment (investigational or control) and age as independent
variables. Vague normal priors (i.e. Nð0, 104Þ) were used for the log-hazard ratios of treatment and age. To
model the baseline hazard, we used the piecewise exponential speciﬁcation given by Murray et al.8 (see the
supplementary material). In all methods except the method of Murray et al., a proportional hazards
speciﬁcation was used to model the treatment eﬀect and the diﬀerences between trials. Only the method of
Murray et al. allowed for diﬀerences in the shape of the baseline hazard between the historical and the current
data.
4.1 Method-specific settings
For the speciﬁc settings of each method, we followed as much as possible the recommendations in the papers that
originally proposed the methods. In Pocock’s method, the variance of the bias in the log-hazard ratio between the
historical controls and the current controls was set to 0.01, which yields a standard deviation of the hazard ratio ofﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
expð0:01Þðexpð0:01Þ  1Þp ¼ 0:10.1 In sensitivity analyses, the variance of the bias was varied to 0.0025 and 0.04.
The power prior was applied using a weight of ¼ 0.5. For the MPP, a Beta(1,1) prior (i.e. a uniform distribution
on [0,1]) was used for . In sensitivity analyses, we varied this prior to Beta(0.5,0.5) (i.e. Jeﬀreys prior) and
Beta(2,2). For the MAP approach, the data of all trials were combined in a single analysis; this approach is
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referred to as the meta-analytic-combined approach by Schmidli et al.6 A half-normal prior was used for the
between-study standard deviation  of the log-hazard ratio. Following Neuenschwander et al.,
5 the standard
deviation parameter of this half-normal distribution was set to 0.5 and was varied to 0.25 and 1 in sensitivity
analyses. The standard deviations of 0.25, 0.5 and 1 are considered to represent a moderate, substantial and large
amount of between-trial heterogeneity, respectively.26
To implement the robust MAP approach, the posterior of the historical data for the piecewise constant baseline
log-hazard, the covariate eﬀects on the log-hazard scale and the logarithm of 2 was approximated with a
multivariate normal distribution. This multivariate normal distribution was then used as prior MAP in the
analysis of the current data. The robust component robust was created by multiplying the variance of logð2Þ in
MAP by 10, and this component was given a weight of wr ¼ 0:1. We also implemented a version of the robust
MAP approach where the variances and covariances of all parameters in robust were increased by a factor 10.
However, the results were very similar to the version in which only 2 was robustiﬁed, and we thus do not report
the results of this alternative approach.
The TTP approach was implemented by testing the eﬀect of trial in a Cox proportional hazards model for
overall survival with trial, treatment and age as independent variables. In case of a signiﬁcant eﬀect (p< 0.05) of
trial, we preferred the ‘Current data’ approach; otherwise, the ‘Pooled data’ approach would be used. The method
of Murray et al. was run using the priors and settings proposed in their paper.8
4.2 Posterior sampling
For each Bayesian method, the posteriors were calculated using 500,000 iterations of MCMC sampling, after
100,000 burn-in iterations. This large number of iterations was necessary to ensure convergence in the algorithms
for the power prior and the MPP. Convergence was assessed using Geweke’s diagnostic. The power prior, the
MPP and the method of Murray et al. were applied to a situation with multiple historical trials by pooling the data
of the historical trials, so that diﬀerences between these historical trials are not modelled explicitly.
All statistical analyses were done using R and JAGS. JAGS was used for posterior sampling for the (robust)
MAP approach, the method of Murray et al., the pooled analysis of all trials and the analysis of the current data.
For the method of Murray et al., we used the code that was made available by the authors of that paper.8 The
MCMCpack package was used to perform posterior sampling and compute the scaling constant for the power
prior and the MPP.
4.3 Results
Table 2 shows the posterior distribution of the hazard ratio of the investigational treatment (G-CSF priming) in
HOVON 42A using diﬀerent methods for including historical data. The 95% credible interval (CI) of the hazard
ratio includes the value 1 for all methods, so that there is insuﬃcient evidence to conclude that G-CSF priming
aﬀects survival. Nevertheless, the inclusion of historical data changes the results of the analysis considerably, as is
demonstrated by the diﬀerence in estimated hazard ratio between the ‘Current data’ and ‘Pooled data’ results.
Including historical data reduces the posterior standard deviation of the intervention eﬀect.
Table 2. HOVON data: Posterior distribution of the hazard ratio of the treatment effect in the HOVON
42A trial, using different methods for including historical data.
Method Mean
Standard
deviation 2.5% 97.5%
Current data 1.118 0.132 0.882 1.398
Pooled data 0.941 0.083 0.787 1.113
Pocock’s method 1.008 0.100 0.823 1.219
Power prior with ¼ 0.5 0.971 0.090 0.805 1.156
MPP 0.979 0.095 0.809 1.178
MAP approach 1.066 0.127 0.843 1.338
Robust MAP approach 1.094 0.125 0.871 1.361
Method of Murray et al. 1.107 0.129 0.876 1.380
TTP approach 0.941 0.083 0.787 1.113
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The results in Table 2 enable us to assess how much borrowing of information occurs with the diﬀerent
methods, based on how close the posterior results are to either the ‘Current data’ or the ‘Pooled data’ analysis.
The power prior with a¼ 0.5 includes half of the historical data as prior information, but the posterior mean of the
hazard ratio using the power prior lies closer to the posterior mean of the ‘Pooled data’ analysis. A similar amount
of borrowing is found using the MPP, and less borrowing occurs using Pocock’s method. The MAP approach, the
robust MAP approach and the method of Murray et al. lead to a relatively small amount of borrowing in the
HOVON data. In the TTP approach, the eﬀect of trial was not signiﬁcant (p¼ 0.22), so that this approach uses the
results of the ‘Pooled data’ analysis.
Table 3 shows, for each method, the posterior distributions of the parameters that represent the between-trial
heterogeneity and the amount of borrowing from the historical data; see also Figures S1 and S2 in the
supplementary material. In Pocock’s method, the main parameter for the between-trial heterogeneity (i.e. 2 ) is
not estimated but chosen in advance. However, it is useful to investigate the posterior distributions of the trial-
speciﬁc biases . Because  is modelled on a log-hazard scale, the associated hazard ratio is given by expðÞ. The
95% CIs of expðÞ include the value 1 for both HOVON 29 and HOVON 42, indicating that these trials do not
diﬀer from HOVON 42A. The posterior standard deviations of the hazard ratios are slightly lower than the prior
standard deviation of 0.10.
The MAP approach estimates the between-trial heterogeneity, but the 95% CIs of the between-trial standard
deviation  (0.01–0.65, measured on the log-hazard scale) and the trial-speciﬁc hazard ratios (i.e. expðkÞ) are
wide. However, the posterior distribution in Figure S1 shows that the data provide evidence for at least some
between-trial heterogeneity. This ﬁgure also includes the posterior of  if only the historical data are included,
which is used to construct the prior MAP in the robust MAP approach. Due to the addition of the robust
component, the posterior 95% CI of  in the robust MAP approach is even wider than in the MAP approach
without robustiﬁcation. The 95% CI for the relative weight of the historical data () in the MPP is wide (0.12–
0.97), but the posterior in Figure S2 shows that values of  between 0.2 and 0.8 are most likely given the observed
data. The sensitivity analyses in Figures S1 and S2 show that the results of the MAP approach are somewhat
sensitive to the prior ð2Þ. A relatively limited sensitivity to ðÞ was observed for the MPP.
In the method of Murray et al., separate precision parameters are estimated for the between-trial heterogeneity
regarding the covariate eﬀects (i.e. age) and the baseline hazard. These parameters were denoted as 	
p and 	 by
Murray et al., respectively. Table 3 presents the posterior distributions of the associated standard deviations,
i.e. 
p ¼ 	0:5
p and  ¼ 	0:5 , which are the standard deviations of the parameters (on the log-hazard scale) for the
current trial, conditional on the parameters for the historical trials. The prior ðÞ consists of a ‘spike’ (i.e. a point
mass representing near-homogeneity of historical and current data) at  ¼ 2000:5 ¼ 0:071 and a ‘slab’
Table 3. HOVON data: Posterior distributions of parameters for the amount of borrowing from
historical data, using different methods for including historical data.
Method Mean
Standard
deviation 2.5% 97.5%
Pocock’s method
expðÞ for HOVON 29 1.117 0.070 0.985 1.261
expðÞ for HOVON 42 1.047 0.069 0.919 1.188
MPP
 0.527 0.240 0.120 0.968
MAP approach
 0.198 0.166 0.014 0.648
expðkÞ for HOVON 29 1.097 0.183 0.810 1.527
expðkÞ for HOVON 42 1.031 0.168 0.749 1.419
expðkÞ for HOVON 42A 0.922 0.147 0.640 1.224
Robust MAP approach
 0.160 0.292 0.003 0.741
expðkÞ for HOVON 42A 0.953 0.110 0.683 1.145
Method of Murray et al.
Age 0.442 0.590 0.071 1.749
 0.071 0.000 0.071 0.071
Note: An explanation of the symbols can be found in the text.
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(representing between-trial heterogeneity) between  ¼ 20:5 ¼ 0:71 and  ¼ 100, as was used by Murray et al.
The posterior mass of the spike part of ðÞ was 1, so that the possibility of substantial heterogeneity was rejected.
Accordingly, the posterior standard deviation of  was 0.
5 Simulation study
We evaluated all methods that were applied to the HOVON data using a simulation study. The purpose of this
simulation study was (a) to assess the bias and precision of the estimates and the frequentist characteristics, (b) to
determine if the methods produce biased results if there is a time trend in the outcome and (c) to assess the eﬀects
of the between-trial heterogeneity on the performance of these methods. The design of the simulation study was
motivated by the HOVON data.
5.1 Design of the simulation study
Survival data were generated according to a Weibull distribution with density f ðxja, biÞ ¼
ða=biÞðx=biÞða1Þ expððx=biÞaÞÞ, with shape parameter a¼ 0.6 and scale parameter bi depending on the trial and
the treatment arm. This scale parameter was deﬁned such that there were proportional hazard eﬀects of trial,
intervention, and, in some scenarios, a time trend. The value of bi was chosen as bi ¼ expðbi Þ1=0:6, with
bi  Nð
0 þ 
1Triali þ 
2Interventioni, 2bÞ, where Trial indicates the trial number with values 1, 2 or 3 for the
historical trials and 4 for the current trial, Intervention is 0 for the control arm and 1 for the investigational arm,
and 2b is the variance of the trial-speciﬁc eﬀect on the log-hazard scale. The baseline log-hazard was set to

0 ¼ 2:5 and the values of 
1, 
2 and 2b were varied between the scenarios of the simulation study. Censoring
dates were generated according to a uniform distribution between t¼ 36 and t¼ 84 months, based on the average
duration of follow-up in the HOVON data.
We considered six scenarios with diﬀerent settings for the level of heterogeneity and the time trend in the
survival outcome. See Table 4 for an overview. The time trend in Scenarios 2 and 3 was simulated by letting the
survival improve with a hazard ratio of 0.95 per trial, so that 
1 ¼ logð0:95Þ; in the other scenarios, 
1 was set to 0.
In Scenario 3, the trial number was included as a covariate in the analysis model, to account for the time trend. In
Scenarios 1, 2 and 3, the standard deviation of the trial-speciﬁc eﬀect on the log-hazard scale was set to b ¼ 0:1,
leading to a standard deviation of the hazard ratio of 0.1. All scenarios were run with two settings for the
intervention eﬀect: (a) a hazard ratio of 0.7 (i.e. 
2 ¼ logð0:7Þ) and (b) no intervention eﬀect (
2 ¼ 0). The
hazard ratio of 0.7 was chosen so that the power of the analysis of the current trial would be approximately 70%.
We simulated 500 data sets with K¼ 3 historical trials and 1 current trial for each scenario. The sample size was
150 patients per arm for each trial, so that a simulated data set included 750 patients in total. The eﬀects of the
settings of the simulation study are visualized in Figure 2, which shows the Kaplan–Meier curves for a simulated
data set in Scenario 1, and in Figures S3 to S8, which present these curves for all scenarios. These ﬁgures include
95% conﬁdence limits (with respect to the trial-speciﬁc eﬀect) of the population survival curves. Because some
methods evaluated in this study were not designed for data sets with multiple historical studies, we also ran the
simulation study with K¼ 1 historical trial, and thus only 450 patients per data set.
To analyse the simulated data, we used the same methods and settings as for the HOVON data, including the
piecewise-constant hazard function proposed by Murray et al., except that the number of intervals with piecewise-
constant hazard was set to 5 (with the time axis partition chosen as the quintiles of the simulated event times), and
Table 4. Scenarios in simulation study.
Scenario Time trend Heterogeneity
Trial number included
as covariate
1: Baseline scenario No time trend b ¼ 0:1 No
2: Time trend, no adjustment expð
1Þ ¼ 0:95 b ¼ 0:1 No
3: Time trend, with adjustment expð
1Þ ¼ 0:95 b ¼ 0:1 Yes
4: No heterogeneity No time trend b ¼ 0:0 No
5: Moderate heterogeneity No time trend b ¼ 0:2 No
6: Large heterogeneity No time trend b ¼ 0:4 No
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only 150,000 MCMC iterations were used in each method. For all scenarios except Scenario 3, we adapted the
code of the method of Murray et al. so that it could be run without covariates in the historical data; all parameters
relating to these covariates were thus removed from the model for these scenarios. Outcome measures were the
bias, posterior standard deviation and root mean square deviation (RMSD) of the log-hazard ratio of the
intervention eﬀect. For each simulated data set, these outcome measures were deﬁned as
Bias ¼ E
2jH,D 
2  
2
 
SD ¼ E
2jH,D ð
2  
2Þ2
 0:5
RMSD ¼ E
2jH,D ð
2  
2Þ2
 0:5
where 
2 is the posterior mean of 
2 and 


2 is the intervention eﬀect used to generate the data.
We also calculated the power (using 
2 ¼ logð0:7Þ) and type I error rate (with no intervention eﬀect) for
rejecting the null hypothesis of no intervention eﬀect, based on the 95% CI of the hazard ratio. All outcome
measures were averaged over the 500 simulated data sets and calculated separately by method and scenario. The
R codes of the simulation study are included in the online supplementary material.
5.2 Simulation results
Tables S1, S2 and S3 in the supplementary material present the average bias, standard deviation and RMSD of the
methods in the simulation study, respectively, including 95% conﬁdence intervals of these averages. Table S1
shows that all methods yield approximately unbiased results if there is no time trend in the outcome. In Scenario 2
(with a time trend in the survival), all borrowing methods, except the TTP approach, yield a biased estimate of the
treatment eﬀect. However, adjusting for this time trend (Scenario 3) eliminates most of this bias.
The average posterior SDs in Table S2 show the precision of the estimated treatment eﬀect. These results can be
used to determine how much information the diﬀerent methods borrow from the historical data, as borrowing
from the historical data increases the precision of the estimates. For all methods, the average standard deviation
tends to lie between the ‘Current data’ and the ‘Pooled data’ analyses, indicating that some but not all of the
historical data are used. Most borrowing of information occurs with Pocock’s method, the power prior, and the
method of Murray et al., and the amount of borrowing in Pocock’s method and the power prior seems unaﬀected
by the between-trial heterogeneity. For the other methods, the amount of borrowing is lower and depends strongly
on the between-trial heterogeneity.
The average RMSDs in Table S3 show to what extent the estimation of the treatment eﬀect is improved by the
use of historical data. In Scenarios 1 to 4, all methods that use historical data perform well, with lower RMSDs
Figure 2. Simulation study: Kaplan–Meier curves of a simulated data set in Scenario 1, including the population survival curves (grey
area) corresponding with the 2.5th and 97.5th percentile of the trial-specific effect.
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than in the ‘Current data’ analysis. However, in Scenarios 5 and 6 (with a moderate or large heterogeneity), only
the MAP approach and the robust MAP approach outperform the ‘Current data’ analysis.
The estimated power and type I error rates in Table 5 show that the ‘Pooled data’ analysis, Pocock’s method,
the power prior and the method of Murray et al. lead to inﬂated type I error rates, especially in Scenarios 2, 5 and
6. The MAP approach, the robust MAP approach and the TTP approach have an estimated type I error rate close
to the nominal rate of 5% in all scenarios, but these methods yield only a modest increase in power compared with
the ‘Current data’ analysis, especially in Scenarios 5 and 6. Of these three methods, the MAP approach without
robustiﬁcation appears to yield the largest increase in power. The MPP oﬀers a more substantial increase in power,
but at the cost of an inﬂated (7.6% and 10.2%) type I error rate in Scenarios 5 and 6.
The estimated power and type I error rates for the simulations with one historical trial (instead of three) are
shown in Table S5. These results were generally similar to the results of the simulations with three historical trials,
though the gain in power due to the inclusion of historical data was much lower. Surprisingly, the MAP approach
and the robust MAP approach performed well in this setting, despite that there were only two trials in the meta-
analysis model.
6 Discussion
Using the HOVON data, several methods for including historical data yielded substantial borrowing of
information from the historical data, and thus greater precision (i.e. lower posterior SDs) of the estimated
treatment eﬀect. However, a prerequisite for including historical data in the analysis of clinical trials is that the
trials are suﬃciently comparable. The validity of the results using historical data may thus be questioned in this
case, as not all of Pocock’s comparability criteria were satisﬁed. The greatest concern was the presence of a time
trend in the survival over consecutive trials, which may be explained by improvements in supportive care and the
consolidation phase treatment.
In the simulation study, the MAP approach yielded the best performance, with increased power and precision in
every scenario (compared to an analysis without historical data), and a type I error rate close to 5%. The type I
error rate was also well controlled in the robust MAP approach and the TTP approach, though the gain in power
Table 5. Simulation study: average power and type I error rate of the 95% credible interval of the treatment effect, based on 500
simulated data sets.
Scenario 1 2 3 4 5 6
Time trend No Yes Yes No No No
Heterogeneity Small Small Small None Moderate Large
Power
Current data 0.690 0.692 0.690 0.662 0.668 0.670
Pooled data 0.842 0.946 0.728 0.876 0.734 0.650
Pocock’s method 0.842 0.930 0.708 0.854 0.750 0.660
Power prior with ¼ 0.5 0.836 0.926 0.706 0.846 0.742 0.646
MPP 0.820 0.906 0.698 0.840 0.734 0.668
MAP approach 0.756 0.794 0.710 0.786 0.714 0.682
Robust MAP approach 0.744 0.772 0.686 0.738 0.700 0.682
Method of Murray et al. 0.826 0.924 0.722 0.858 0.728 0.672
Test-then-pool method 0.716 0.726 0.682 0.796 0.628 0.660
Type I error rate
Current data 0.042 0.040 0.040 0.046 0.040 0.048
Pooled data 0.096 0.162 0.064 0.052 0.254 0.542
Pocock’s method 0.068 0.118 0.038 0.040 0.152 0.428
Power prior with ¼ 0.5 0.068 0.118 0.046 0.036 0.156 0.428
MPP 0.052 0.084 0.040 0.038 0.076 0.102
MAP approach 0.030 0.046 0.040 0.030 0.040 0.048
Robust MAP approach 0.030 0.040 0.040 0.034 0.036 0.048
Method of Murray et al. 0.086 0.138 0.062 0.044 0.144 0.172
Test-then-pool method 0.046 0.062 0.042 0.040 0.042 0.050
Note: The width of each side of the 95% binomial proportion confidence interval (not shown in the table) is approximately 2% to 3% for the type I
error rate and 4% for the power.
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of these methods was slightly lower. The robust MAP approach provides additional safeguards for situations
where the heterogeneity between the current trial and the historical trials exceeds the heterogeneity among the
historical trials. Because this situation was not included in the design of the simulation study, one may prefer
the robust MAP approach over the MAP approach without robustiﬁcation for some applications. The MPP and
the method of Murray et al. performed well in scenarios with a low between-trial heterogeneity, but had an inﬂated
type I error rate in scenarios with a moderate or large heterogeneity. These methods all demonstrated adaptive
borrowing of information: the amount of historical data used was lower in scenarios with higher between-trial
heterogeneity. There is no adaptive borrowing in Pocock’s method and the power prior, because the parameters
for the between-trial heterogeneity (i.e.  in the power prior and 2 in Pocock’s method) are set in advance. We
generally do not recommend to use these two methods, as they do not provide adequate safeguards against large
diﬀerences between trials. Also, none of the methods showed adaptive borrowing in case of a time trend in the
survival, suggesting that the methods are not robust to such biases in the historical data.
The simulation results may be used to determine which method for including historical data is most suitable
for the HOVON data. The parameterisation of the heterogeneity in the MAP approach is the same as in the
design of the simulation study, which means that the distribution of  in the MAP approach can be linked to
the values of 
 in the scenarios of the simulation study. The values of 
 ¼ 0:1, 
 ¼ 0:2 and 
 ¼ 0:4,
which were considered to represent low, moderate and high levels of heterogeneity, correspond with the 31st,
64th and 90th percentiles of the posterior distribution of  in the HOVON data, respectively. Therefore, it is
not clear which scenario in the simulation study best represents the diﬀerences among the HOVON trials. We
should thus adopt a method that performs well in all scenarios, such as the MAP approach or the robust MAP
approach.
In the simulation study, all methods were compared using settings proposed in previous literature. However, the
simulation results suggest that some of these settings may not be optimal. The MPP borrowed a relatively large
amount of information from the historical data, both in the HOVON data and the simulation study, leading to
inﬂated type I error rates. This may be due to the Beta(1,1) prior for , which assigns little probability to values of
 that lead to an exclusion of the historical data. A more sceptical prior, with more probability mass assigned to
values close to 0, could lead to a better trade-oﬀ of power and type I error rate. Such overenthusiastic borrowing
from the historical data was also observed for the method of Murray et al. Future simulation studies could
investigate the optimal settings for the priors of these methods. The most appropriate implementation of the
robust MAP approach for models with multiple parameters, including which parameters should be ‘robustiﬁed’,
should also be further investigated.
Ideally, one would use the inclusion of historical data at the design stage of a new trial, so that fewer (control)
patients have to be recruited. Using standard formulas for power analysis, the increase in power of the MAP
approach versus the ‘Current data’ analysis from 0.69 to 0.76 in Scenario 1 and from 0.67 to 0.71 in Scenario 5
corresponds with approximate reductions of the sample size of 14% and 10%, respectively. See also Table S4 in
the supplementary material and the results for the prior eﬀective sample size reported by Neuenschwander et al.5
Although such sample size reductions are useful, they are not spectacular. Disadvantages of reducing the number
of current controls are that (a) it becomes more diﬃcult to detect whether the current data are in conﬂict with the
historical data, and (b) in case of such a conﬂict, the methods with adaptive borrowing may discard the historical
data, leaving insuﬃcient power for the analysis of the current trial. This latter problem may be addressed by
implementing adaptive randomisation designs.6
The HOVON data were chosen in this study because these data have characteristics that are advantageous for
the use of historical data, as these are consecutive trials on the same disease and sponsored by the same
organisation. Nevertheless, we found that not all of Pocock’s criteria were satisﬁed. The requirements that the
historical trials (a) had the same control arm treatment, (b) were recent trials and (c) were conducted by the same
organisation seem diﬃcult to satisfy in general. There are not many research organisations that perform several
trials on the same disease in a relatively short period of time, especially not in an academic setting, though this
could be more common in industry-sponsored trials. Further research on how stringently such comparability
criteria should be applied thus seems warranted.
The results of the HOVON data also illustrate the dangers of including older historical data in situations where
the outcome improves over time. Such improvements in the outcome violate the exchangeability assumption
underlying Pocock’s method and the MAP approach, because the between-trial diﬀerences do not have mean
zero in that case. Borrowing of information from historical controls may then lead to an upward bias in the
estimated treatment eﬀect. We therefore recommend to carefully check the data for any time trends in the
outcome, especially when the historical data are not recent.
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Several limitations of the analyses in this article should be mentioned. We compared diﬀerent methods using
only a single application in which there was no signiﬁcant eﬀect of the investigational treatment; other data sets
could potentially yield diﬀerent results. However, we believe that the HOVON trials are representative for other
clinical contexts where historical data are available. The amount of borrowing of information from the historical
data would likely have been similar if there had been a signiﬁcant treatment eﬀect in the current trial, as in most
methods the amount of borrowing is mainly determined by the diﬀerences among the control arms of all trials. In
addition, we made no attempt to ﬁnd the optimal settings and priors for the compared methods and instead relied
on the values suggested in previous literature. It is possible that some methods would perform better with diﬀerent
priors, especially for the parameters that determine the amount of borrowing. The implementations of the power
prior, the MPP and the method of Murray et al. did not take into account that there were multiple historical trials,
and instead used the pooled data of the historical trials. Finally, we did not consider all available methods for
including historical data, such as the commensurate power prior.23
7 Conclusions
It seems possible to improve the power and precision of the analysis of a clinical trial and simultaneously control
the type I error rate, by including historical trials that are suﬃciently comparable to the current trial. To do so, it is
necessary to use a method that accounts for between-trial heterogeneity, such as the MAP approach or the robust
MAP approach, so that the historical data are included adaptively. However, in many practical settings, historical
data that satisfy the criteria for comparability may not be available. To ensure that these methods will be accepted
by regulatory authorities and adopted by clinical researchers, further research is needed to determine in what
situations the application of these methods is feasible.
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